Haloperidol analogs
Haloperidol analogs that conforms to the structural formulae: wherein: R is H, or —(CH 2 ) n —OH, n is an integer from 0 to 2, and A is a heterocyclic bridging group, consisting essentially of carbon and at least one nitrogen atom, which effectively maintains the distance between the moieties connected thereby such that the compound (1) is incapable of metabolizing to BCPP + like species, (2) has an affinity for the D2 receptor subtype of 15<D2<250 and (3) functions as a dopamine receptor antagonist, or the structural formulae: wherein: R 1 is H, or —(CH 2 ) n —OH, n is an integer from 0 to 2, B is an aza- or diaza-bicyclo group, which effectively maintains the distance between the moieties connected thereby such that the compound is incapable of metabolizing to BCPP + like species; and Z is —CH— or N; and pharmaceutically acceptable salts, esters, derivatives, metal complexes, conjugates and prodrugs thereof.
1. A haloperidol analog having one of the formulae:
2. A method for treating a mammalian patient suffering from psychosis comprising administration to the patient of a therapeutically effective amount of a haloperidol analog of claim 1 .
3. A pharmaceutical composition comprising a haloperidol analog of claim 1 and a pharmaceutically acceptable carrier.